This study is a double blind clinical trial. Ninety thalassemic patients that refer to Shohada Hospital Lordegan-University of Medical Sciences were selected. All patients have blood transfusion and consume Desferal.
Main inclusion criteria for selected Patients are ages of 10-60 years that have regular blood transfusion and chelation intermittent at least four days a week. All
Patients under ten years old, hepatitis and HIV positive, heart failure, kidney disease, pregnant women and patients who don’t respond to chelation therapy will be excluded.
Patients will be divided in to two groups randomly. In this way,patients who complete consent, are identifed with numbers. so the patients in each group are selected randomly from among these numbers.. The case group will received daily amount of 300 mg of Oak extract for four months. Control group received placebo for same time.
Placebo and Oak extract will prepare in capsule form and classified as A and B code. Blood sample will be collected from patients before and after of study. Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline phosphatase, triglyceride, total cholesterol, HDL-c, glucose, uric acid, bilirubin, Fe, BUN and creatinine, Malone dialdehayde, Ferritin, carbonylated protein, catalase, superoxide dismutase, glutathione peroxidase and total antioxidant capacity of all sample will be measured.